focus -WSS

focus

author：hotspot 2025-09-05 11:19:25 - browse：2718

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug Krazati, for $4.8 billion in cash in a deal that shows the continued interest of large pharmaceutical firms in relatively small “bolt-on” acquisitions.

Bristol said that it would pay $58.00 per share for Mirati, and would hold another $12.00 per share, or a total of $1 billion, to be paid if one of two different applications for an additional use for Krazati is approved within seven years after the merger closes.

Chris Boerner, Bristol’s chief operating officer and CEO-elect, said in a statement that Mirati had several cancer drugs in development that could deliver sales in the latter half of the decade and beyond, when investors worry that Bristol will need new products to sustain its growth.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Heart attack and stroke risk calculators need revising

knowledge

WSS

Activists slam private health insurers over coverage restrictions

United colonoscopy coverage change 'may cost lives,' doctors say

Hollywood unions extend contract negotiations for actors

Time to name cancers by genetics, not organ of origin, expert says

Apple is now the first public company to be valued at $3 trillion

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

focus

focus

hotspot

Alkermes shareholders re

Trump demands the U.S. pay no more for drugs than other countries … again

In Memoriam: Notable people who died in 2023

As demand for Covid shots wanes, Moderna seeks its next success

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Vertex non

Medical records are filled with copy

Hepatitis C has a cure — but many Americans still lack access to it

New air purifier tech could be key to improving indoor air quality

ChatGPT in medicine: STAT answers readers' burning questions

leisure time

Cancer drug shortages should be causing more outrage

Vertigo drug brings hope for rare neuron disorder, Niemann

Woodcock on FDA’s accelerated approval and her next chapter

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Time to name cancers by genetics, not organ of origin, expert says

Biden administration opens offers in Medicare drug price negotiations

entertainment

hotspot

knowledge

explore